Fernandes NC, Fernandes MLF, Cuzzi T

Idioma: Español
Referencias bibliográficas: 13
Paginas: 218-222
Archivo PDF: 429.07 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fernandes NC, Cardoso ICL, Serpa SS, Rettore FC, et al. Granulomatose de Wegener localizada: relato de caso. An bras Dermatol 1996; 71: 41-4.

2. Fernandes NC, Paes C, Castilho M, Maceira J. Granulomatose de Wegener localizada com manifestação ocular: relato de caso. An bras Dermatol 1998; 73: 107-10.

3. Lloyd G, Lund VJ, Beale T, Howard D. Rhinologic changes in Wegener’s granulomatosis. J Laryngol Otol 2002; 116: 565-9.

4. Galli J, Conna L, Larocca LM. Unusual case of pharyngeal-laryngeal Wegener’s granulomatosis. Acta Otorhinolaryngol 2001; 21: 187-91.

5. Paulsen JI, Rudert H. Manifestations of primary vasculitis in the ENT region. Z Rheumatol 2001; 60: 219-25.

6. Kuchel J, Lee S. Cutaneous Wegener’s granulomatosis: a variant or atypical localized form? Australas J Dermatol 2003; 44: 129-35.

7. Fechner FP, Faquin WC, Pilch BZ. Wegener’s granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryng 2002; 112: 1945-50.

8. Flach AJ. Ocular manifestations of Wegener’s granulomatosis. JAMA 1995; 274: 1199-200.

9. Sneller MC. Wegener’s granulomatosis. JAMA 1995; 6: 2938-42.

10. Dilhuydy MS, Mercié P, Viallard JF, Dumont T, et al. Natural killer cell nasal lymphoma mimicking localized Wegener’s disease. Rev Med Interne 2001; 22: 571-75.

11. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10.

12. Stone JH, Uhlfelder ML, Hellmann, Crook S, et al. Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44 (5): 1149-54.

13. Takagi D, Nakamaru Y, Maguchi S, Furuta Y, Fukuda S. Otologic manifestations of Wegener’s granulomatosis. Laryng 2002; 112: 1684-90.